TAR:GET1 Trial Steering Committee (External organisation)

Activity: MembershipCommittee


Steering Committee to a multicentre randomised controlled trial to assess the safety and efficacy of adding rituximab to standard of care in treating acute antibody-mediated rejection in kidney transplantation Transplant Antibody-Mediated Rejection: Guiding Effective Treatments (TAR:GET-1)
Period3 Jan 20192022
Held atTAR:GET1 Trial Steering Committee, United Kingdom
Degree of RecognitionNational